EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieVergleichsstudieOpen Access · CC BY 4.0

Randomized Clinical Trial on the Efficacy of Oral Tranexamic Acid Versus Topical Tranexamic Acid in Treatment of Melasma

Behrooz Heidary iD, Golnaz Alsadat Habibzadeh Meibodi iD, Mohammad Ebrahimzadeh Ardakani iD, Vahid Ramezani iD, Fateme Heidari iD

Journal of Cosmetic Dermatology · 2025

DOI: 10.1111/jocd.70428 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift Journal of Cosmetic Dermatology, 2025. Verfasst von Behrooz Heidary und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmaceutics, Faculty of Pharmacy, Shahid Sadoughi University of Medical Sciences, Yazd, Iran. Hauptthemen laut MEDLINE: Tranexamic Acid, Melanosis, Antifibrinolytic Agents. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 18 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Melasma is a prevalent skin condition that primarily affects females of reproductive age. Despite the various available treatments, managing melasma is challenging due to frequent relapses and partial responses. Tranexamic acid (TXA) has gained attention as a potential treatment because of its antifibrinolytic and anti‐melanogenic properties. However, there is still limited information on the efficacy of oral versus topical TXA formulations.

Aim

The present investigation explored the efficacy and safety of topical versus oral TXA in melasma patients to determine whether topical administration could provide a viable alternative with improved tolerability. Patients/Methods In this single‐center randomized trial, 50 melasma patients received oral TXA (250 mg twice daily) or topical TXA (a 5% cream applied twice daily) for 12 weeks. Melasma severity was measured using the Melasma Area and Severity Index (MASI) score at baseline and after 3 months. Data analysis was performed using SPSS version 24, with p < 0.05 considered statistically significant.

Results

Fifty female patients (mean age≈39.9 years) were equally randomized to the oral and topical TXA group. One patient in the topical group discontinued treatment due to sensitivity, while all in the oral group completed the study. At baseline, MASI scores were not significantly different between the two groups ( p = 0.28). After 12 weeks, both groups demonstrated significant reductions in MASI scores (oral group: 58.86%; topical group: 50.88%; p = 0.001 for each), though the difference was insignificant.

Discussion

Fifty female patients (mean age≈39.9 years) were equally randomized to the oral and topical TXA groups. One patient in the topical group discontinued treatment due to sensitivity, while all in the oral group completed the study. Baseline MASI scores were similar ( p = 0.28). After 12 weeks, both groups demonstrated significant reductions in MASI scores (oral group: 58.86%; topical group: 50.88%; p = 0.001 for each), though the difference was not statistically significant.

Conclusion

Both forms of TXA are effective with low side effects. The choice between oral and topical TXA can depend on patient preference and convenience.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Tranexamic AcidMelanosisAntifibrinolytic AgentsHumansFemaleAdultAdministration, OralTreatment OutcomeMiddle AgedAdministration, CutaneousSeverity of Illness IndexYoung AdultSkin CreamAdministration, Topical

Stichwörter der Autor:innen

MASI scoremelasmaoral tranexamic acidtopical tranexamic acidtranexamic acid

Substanzen

Tranexamic AcidAntifibrinolytic Agents

Autor:innen und Institutionen

  • Department of Pharmaceutics, Faculty of Pharmacy, Shahid Sadoughi University of Medical Sciences, Yazd, Iran.
  • Department of Dermatology, Shahid Sadoughi University of Medical Sciences, Yazd, Iran.
  • Department of Medicine, Yazd Branch, Islamic Azad University, Yazd, Iran.

ORCID-Profile: Behrooz Heidary, Golnaz Alsadat Habibzadeh Meibodi, Mohammad Ebrahimzadeh Ardakani, Vahid Ramezani, Fateme Heidari

Zitieren

APA

Heidary, B., Meibodi, G. A. H., Ardakani, M. E., Ramezani, V., & Heidari, F. (2025). Randomized Clinical Trial on the Efficacy of Oral Tranexamic Acid Versus Topical Tranexamic Acid in Treatment of Melasma. Journal of Cosmetic Dermatology. https://doi.org/10.1111/jocd.70428

Vancouver

Heidary B, Meibodi GAH, Ardakani ME, Ramezani V, Heidari F. Randomized Clinical Trial on the Efficacy of Oral Tranexamic Acid Versus Topical Tranexamic Acid in Treatment of Melasma. Journal of Cosmetic Dermatology. 2025. doi:10.1111/jocd.70428

BibTeX
@article{Heidary2025,
  author = {Heidary, Behrooz and Meibodi, Golnaz Alsadat Habibzadeh and Ardakani, Mohammad Ebrahimzadeh and Ramezani, Vahid and Heidari, Fateme},
  title = {Randomized Clinical Trial on the Efficacy of Oral Tranexamic Acid Versus Topical Tranexamic Acid in Treatment of Melasma},
  journal = {Journal of Cosmetic Dermatology},
  year = {2025},
  doi = {10.1111/jocd.70428}
}
Kostenlos starten →